Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grace Gao

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Chinese Medical Journal|May 26, 2026
Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trialKejing Tang, Fengying Wu, Fang Yang, et al.
Journal of Hematology & Oncology|February 16, 2021
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyHuiqiang Huang, Jun Zhu, Ming Yao, et al.
Annals of Hematology|January 17, 2024
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumabMin Qing, Tianyuan Zhou, Tatiana Perova, et al.
Applied Clinical Informatics|May 7, 2023
Data Science Implementation Trends in Nursing Practice: A Review of the 2021 LiteratureAnn M Wieben, Rachel Lane Walden, Bader G Alreshidi, et al.
Nature Medicine|September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trialByoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS StudyMatthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Chinese Medical Journal|May 26, 2026
Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trialKejing Tang, Fengying Wu, Fang Yang, et al.
Journal of Hematology & Oncology|February 16, 2021
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyHuiqiang Huang, Jun Zhu, Ming Yao, et al.
Annals of Hematology|January 17, 2024
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumabMin Qing, Tianyuan Zhou, Tatiana Perova, et al.
Applied Clinical Informatics|May 7, 2023
Data Science Implementation Trends in Nursing Practice: A Review of the 2021 LiteratureAnn M Wieben, Rachel Lane Walden, Bader G Alreshidi, et al.
Nature Medicine|September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trialByoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS StudyMatthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.
Pageof 5